Article

When PSMA Is Not Enough: The Diagnostic Blind Spots of PSMA PET/CT and the Added Value of [¹⁸F]FDG in High-Risk Prostate Cancer: Dual-Tracer Cohort Study

2026-05-21

Abstract excerpt

<title>Abstract</title> <p> <bold>Purpose:</bold> PSMA PET/CT has transformed prostate cancer management, yet its diagnostic utility is not absolute. It fails to detect PSMA-suppressed disease variants, including treatment-induced neuroendocrine prostate cancer (t-NEPC) and dedifferentiated tumors, and is inherently blind to second primary malignancies (SPMs). This study evaluated the additional diagnostic yiel...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c5371415-c03c-5aef-9527-5ff305def58c
DOI: 10.21203/rs.3.rs-9598282/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

When PSMA Is Not Enough: The Diagnostic Blind Spots of PSMA PET/CT and the Added Value of [¹⁸F]FDG in High-Risk Prostate Cancer: Dual-Tracer Cohort StudyDOI 10.21203/rs.3.rs-9598282/v1Read

Beyond PSMA: The essential complementary role of MRI in staging prostate cancer with Low-PSMA expression phenotypes.Semantic proximity Read

Bivariate Diagnostic Paired Meta-Analysis at the Patient Level: Direct Validation of PSMA-PET against Conventional Imaging Across All T/N/M Staging Dimensions in Primary Intermediate- to High-Risk Prostate CancerSemantic proximity Read

Redefining Prostate Cancer Precision: Radiogenomics, Theragnostics, and AI- Driven BiomarkersSemantic proximity Read

Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic FrontiersSemantic proximity Read

Dual-tracer PET/CT identifies an aggressive PSMA-negative/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer.Semantic proximity Read

Dual-Tracer 18 F-FDG and 68 Ga-PSMA PET/CT Imaging of Heterogeneous Phenotypes of Metastatic Castration-Resistant Prostate Cancer for Predicting Response to Novel Hormone Therapy.Semantic proximity Read

Follow-up Analysis of Intermediate-risk Prostate Cancer Patients Staged With Psma PET/CTSemantic proximity Read

Distinct prostate cancer neuroendocrine subtypes predict prognosis and guide personalized prostate-specific membrane antigen-targeted therapySemantic proximity Read

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.Semantic proximity Read

Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects.Semantic proximity Read

Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identificationSemantic proximity Read